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Abstract
Background: Gastrointestinal hormones, such as 
glucagon- like peptide (GLP-1), have been hypothesized to 
play a role in the pathogenesis of obesity-related complica-
tions. However, few data are available in youth. The objec-
tive of this study was to investigate the GLP-1 response to 
oral glucose load in obese pre-pubertal children and its 
relationship with insulin secretion.
Methods: Ten pre-pubertal obese children [five boys; 
10.5±1.6 years; body mass index-standard deviation score 
(BMI-SDS): 2.2±0.5] and 10 controls (eight boys; 9.9±1.2 years; 
BMI-SDS: –0.7±0.5) underwent a modified oral glucose tol-
erance test (OGTT) to evaluate post-load glucose, insulin 
and GLP-1 responses. Insulin sensitivity [homeostasis model 
assessment of insulin resistance (HOMA-IR), whole body 
insulin sensitivity index (WBISI)] and secretion [HOMA-
beta, insulinogenic index (IGI)] indexes, area under the 
curve (AUC) for glucose, insulin and GLP-1 were calculated.
Results: In obese children GLP-1 AUC values were higher 
and correlated with BMI-SDS (r = 0.45; p = 0.04), HOMA-IR 
(r = 0.53; p = 0.01) and fasting glucose (r = 0.68; p = 0.001).
Conclusions: Obese children showed an increased GLP-1 
response to oral glucose. These changes might likely rep-
resent a compensatory mechanism to avoid post-prandial 
hyperglycemia and allow a normal glucose tolerance.
Keywords: diabetes; GLP-1; gut hormones; obesity.
Introduction
Despite being a clear tendency towards a stabilization 
of the obesity epidemic in children and adolescents its 
prevalence remains higher than ever before. Around 22 
million children worldwide are obese [1–5], represent-
ing a serious public health problem [6]. In children and 
adolescents obesity is associated with an increased risk 
of developing insulin resistance (IR) and type 2 diabe-
tes (T2D). Impaired β-cell function has been shown to 
be one of the key factors in defining the risk of impaired 
glucose metabolism. In young adults bariatric surgery 
approach is an effective treatment for obesity-related 
comorbidities such as T2D, hypertension and dyslipi-
demia. Interestingly, studies have shown early resolu-
tion of T2D sometimes even within days of the surgery. 
These effects may be documented even prior to weight 
loss and therefore might be related to changes in hor-
monal pathways achieved early after the surgery proce-
dure. The entero-insular axis might be postulated to be 
one of the major factors explaining all these metabolic 
changes. In fact bariatric surgery restores the impaired 
gastrointestinal hormones secretion related to obesity, 
particularly glucagon-like peptide-1 (GLP-1) concentra-
tion. GLP-1 is both a gut hormone and a neuropeptide 
produced by post translational processing of the pre-
pro-glucagon gene. It is secreted from the L-cells in the 
distal gastrointestinal tract in response to food inges-
tion in the gut. GLP-1 levels are low before a meal and 
increase after a meal; it enhances glucose dependent 
insulin secretion, suppresses glucagon secretion and 
inhibits gastric emptying [7, 8]. Therefore, as GLP-1 is 
a main inductor of postprandial insulin secretion, it 
makes a significant contribution to the overall post-
prandial glucose metabolism.
The role of gastrointestinal hormones and especially 
of GLP-1, one of the most relevant incretin hormones, in 
childhood obesity is poorly understood [9]. Contrasting 
data on GLP-1 concentrations in obese subjects have been 
reported. Some authors documented lower fasting GLP-1 
levels and attenuated GLP-1 response to oral nutrient in 
obese individuals. Others also found an enhanced GLP-1 
response to meal ingestion in obese humans and rats 
[10–14]. Although IR and subtle alterations of glucose 
metabolism might be already detected in pre-pubertal 
obese children, T2D is very uncommon in this age group. 
Although several mechanisms might be postulated, the 
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presence of a more effective gut hormone production 
might be one of the possible underlining mechanisms.
Therefore, the aim of this study was to investigate the 
GLP-1 response to oral glucose load in obese pre-pubertal 
children and its relationship with insulin secretion com-
pared to healthy matched controls.
Materials and methods
Study populations
Ten Caucasian pre-pubertal obese children [five boys and five girls; 
mean age (±SD): 10.5±1.6 years] and 10 normal-weight age-matched 
pre-pubertal controls [eight boys and two girls; mean age (±SD): 
9.9±1.2 years] were enrolled in the present study. Obese children, 
referred to the Auxo-Endocrinology Service of the Department of 
Pediatrics, University of Chieti, Italy, were affected by overweight or 
obesity [body mass index (BMI) > 85° percentile for age and sex] [15]. 
Normal-weight controls (BMI < 85° percentile) were recruited among 
children referred to the Auxo-Endocrinology Service of the Depart-
ment of Pediatrics, University of Chieti, Italy for occasional hyper-
glycemia. None of the control group showed alterations in glucose 
metabolism after glucose load.
For all subjects, the absence of chronic or acute disease, malnu-
trition and use of medications were used as inclusion criteria.
All children underwent a detailed clinical history and family his-
tory and a complete physical examination including anthropometric 
parameters (height and weight). All children were pre-pubertal on 
the basis of breast development in girls and genital development in 
boys according to the criteria of Tanner [16].
All subjects performed a modified oral glucose tolerance test 
(OGTT). Glucose, insulin and GLP-1 concentrations after glucose load 
were evaluated.
The study was approved by the Ethical Committee of the Univer-
sity of Chieti. Written informed consent was obtained from all par-
ents and oral consent from children.
Anthropometric measurements
Body weight was measured using a standard balance with a variabil-
ity of 0.1 kg, and height was determined with Harpenden taximeter to 
the nearest 0.1 cm. Body mass index (BMI) was calculated as the ratio 
between weight in kg and height in meters squared, while standard 
deviation score (SDS)-BMI for age and sex as the difference between 
the observed value and the reference mean for age and sex, divided 
by the corresponding standard deviation based on published norma-
tive Italian data [15].
Laboratory procedures
Modified OGTT: Each subject was tested from 8:00 to 9:00 AM, after 
an overnight fast. After insertion of an intravenous catheter, blood 
samples were drawn for the measurement of baseline glucose and 
insulin levels. Thereafter subjects underwent a modified OGTT with 
measurement at 0, 15, 30, 60, 90, 120  min of glucose and insulin 
 levels and with measurements at 0, 5, 10, 15, 20, 30, 60, 90, 120 min 
of GLP-1 levels. Blood samples were collected on ice into tubes con-
taining dipeptidyl peptidase IV inhibitor. After centrifugation at 4 °C, 
plasma samples were processed into different aliquots and frozen at 
–70 °C until analysis.
Formula
Homeostasis model assessment of insulin resistance (HOMA-IR) was 
calculated by the equation fasting insulin (mU/L) × fasting glucose 
(mmol/L)/22.5 [17].
Whole body insulin sensitivity index (WBISI) was calculated as: 
{10/[fasting glycemia (mg/dL) × fasting insulin (μU/mL) × mean con-
centration of glucose (mg/dL)*mean concentration of insulin (μU/
mL)]1/2} [17].
Homeostasis model of assessment-beta (HOMA-β) was cal-
culated as: [20 × fasting insulin (μU/mL)]/[fasting glucose (mmol/
mL)–3.5] [18].
Insulinogenic index (IGI) was defined as: δ insulin 0–30 (μU/
mL)/δ glucose 0–30 (mg/dL).
Area under the curve (AUC) values were determined using the 
trapezoidal rule and it was calculated for insulin, glycemia and GLP-1 
during oral tolerance test [19].
Biochemical analysis
Plasma glucose level was determined by using the glucose oxidase 
method and plasma insulin was measured with a two side immu-
noenzymometric assay (AIAPACK IRI; Tosoh, Tokyo, Japan). The limit 
of detection was 0.5 mcU/mL with interassay coefficients of varia-
tion  < 7% for quality control.
Serum GLP-1 levels were determined with immunoenzymomet-
ric assay (Yanaihara Institute Inc., Fujinomiys-Shi Shizuoka, Japan: 
CV% interassay: 9.63~17.57).
Statistical analysis
The statistical analysis was performed using SPSS version 17.0 soft-
ware for Windows (SPSS, Chicago, IL, USA). All data were analyzed 
with Kolmorgorov-Smirnov test and the date not normally distributed 
were log-transformed. All data were expressed as mean±SD. Differ-
ences between obese and control children were assessed by unpaired 
t-test. A linear regression analysis was used to evaluate the associa-
tions between variables of interest. A p-Value  < 0.05 was considered 
statistically significant.
Results
Anthropometric evaluation
Table 1 shows baseline anthropometric and demographic 
characteristics of obese and normal-weight pre-pubertal 
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children. A higher prevalence of females was present in 
the obese group.
There were no significant differences in terms of 
age, height and SDS-height between the two groups. As 
expected, the group of obese children presented a higher 
weight and SDS-weight than the normal-weight group, 
with a higher BMI and SDS-BMI. There were no significant 
differences in terms of volume of glucose solution admin-
istered for the OGTT.
Table 1: Anthropometric parameters and metabolic characteristics 
in obese and normal-weight pre-pubertal children.
Parameters   Controls 
(n = 10)
  Obese 
(n = 10)
  p-Valuea
Sex, male/female   8/2  5/5  0.01
Age, years   9.9±1.2  10.5±1.6  0.33
Weight, kg   30.1±3.4  59.5±10.9   < 0.001
SDS-weight   –0.6±0.5  1.9±0.7   < 0.001
Height, cm   122±42  142.3±5.8  0.16
SDS-height   –0.2±0.2  0.1±0.9  0.23
BMI, kg/m2   16.2±1.0  29.2±3.8   < 0.001
SDS-BMI   –0.7±0.5  2.2±0.5   < 0.001
Fasting glycemia, mg/dL   90.1±4.9  94.2±12.0  0.26
Fasting insulin, μU/mL   6.5±2.0  15.9±10.6  0.02
HOMA-IR   1.4±0.4  3.7±2.5  0.02
WBISI   9.3±2.7  4.7±2.5  0.002
Fasting GLP-1, ng/mL   2.9±0.4  3.5±1.4  0.21
HOMA-β   1.5±0.5  3.6±2.4  0.02
IGI   0.6±0.4  4.8±3.8  0.007
Data are mean±standard deviation. SDS-weight, standard devia-
tion score weight; SDS-height, standard deviation score height; 
BMI, body mass index. SDS-BMI, standard deviation score-body 
mass index; HOMA-IR, homeostasis model of assessment-insulin 
resistence; WBISI, whole body insulin sensitivity index; HOMA-β, 
homeostasis model of assessment-beta; IGI, insulinogenic index. 
aMann-Whitney U-test.
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Figure 1: Insulin and GLP-1 AUC values during the OGTT.
Modified OGTT
Table 1 shows the main metabolic parameters of study 
groups. Fasting glucose and insulin levels were signifi-
cantly higher in obese rather than in control children. 
IR indexes expressed by HOMA-IR and WBISI were also 
significantly increased in obese children while insulin 
secretion indexes (HOMA-beta and IGI) were significantly 
lower. No differences were detected in fasting GLP-1 levels. 
Insulin and GLP-1 excursions during the OGTT are shown 
in Figure 1. Glucose excursions were not statistically dif-
ferent between the two groups (p < 0.05). AUC for insulin 
and AUC for GLP-1 were significantly higher in obese 
subjects, as shown in Figure 1. Linear regression dem-
onstrated a significant association between GLP-1 AUC 
values and BMI-SDS, HOMA-IR and fasting glycemia as 
shown in Table 2. No statistically significant association 
was found with age, sex, BMI, WBISI, HOMA-β.
Discussion
In this study we documented in a group of obese pre-
pubertal children with normal glucose tolerance the pres-
ence of significantly increased GLP-1 AUC values after an 
oral glucose load compared to normal-weight healthy 
subjects matched for age and pubertal stage. In addi-
tion GLP-1 AUC values were significantly correlated with 
indexes of adiposity and IR. These data suggest a potential 
role of GLP-1 secretion in response to oral glucose admin-
istration in the regulation of glucose homeostasis in obese 
pre-pubertal subjects.
In obese children, an attenuated GLP-1 response may 
contribute to impaired insulin response, leading to T2D 
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[20–22]. GLP-1 may also reduce energy intake and enhance 
satiety, likely through the aforementioned delay of gastric 
emptying and specific GLP-1 receptors in the central 
nervous system. Its role in childhood obesity is poorly 
understood, with contradictory post-weight loss level 
changes reported in the literature [20–27]. In an interven-
tion study in obese children, fasting GLP-1 concentrations 
were shown to be independent of age, sex and pubertal 
stage. In addition, although GLP-1 did not differ between 
lean and obese children at baseline, weight loss was asso-
ciated with decreasing GLP-1 which in turn correlated 
with decreases in insulin levels and IR index scores [25]. 
Similarly to previous studies, in our study we did not find 
significant differences in terms of GLP-1 levels between 
obese and control subjects. These effects may be related 
to normal glucose status of the study population evalu-
ated in our study, while changes in fasting GLP-1 levels at 
baseline might be better associated with the development 
of impaired glucose tolerance or T2D.
As recently shown by Manell et  al., obese adoles-
cents with impaired glucose tolerance had lower fasting 
GLP-1 levels than those with normal glucose tolerance, 
suggesting that this is an early-stage abnormality in obe-
sity-related glucose dysregulation [28]. Moreover, obese 
adolescents showed elevated insulin and glucagon levels 
and that the progression to T2D was related to a further 
increase of these hormones as well as an early-phase 
hyperglucagonemic response to OGTT [28]. However, 
further longitudinal studies are required to confirm this 
hypothesis.
Data from previous studies in obese subjects who 
underwent bariatric surgery have postulated a poten-
tial role of gut hormones in restoring glucose metabo-
lism. This is strongly suggested by the development of 
metabolic changes documented early after bariatric 
procedures. In fact gut hormones and especially GLP-1 
concentrations have been shown to be restored after 
Table 2: Factors associated with GLP-1 AUC during the OGTT.
  AUC GLP-1 p (r)
Age   0.31 (0.24)
Sex   0.08 (0.40)
BMI-SDS   0.04 (0.45)
Insulin AUC   0.01 (0.59)
HOMA-IR   0.01 (0.53)
WBISI   0.13 (–0.37)
HOMA B   0.14 (0.35)
Insulinogenic index  0.10 (0.38)
Glucose AUC   0.57 (0.14)
Fasting glycemia   0.001 (0.68)
Significant values are reported in bold.
bariatric surgery, positively affecting β-cell function 
[29, 30]. To date, few data evaluating the role of GLP-1 
concentrations in obese pre-pubertal children are avail-
able, especially evaluating this high risk population in 
a very early phase of the natural history of the devel-
opment of glucose metabolism alteration [31]. There-
fore in this study we evaluated the secretion of GLP-1 in 
response to a stimulus and the presence of any associa-
tions with insulin release in pre-pubertal obese children 
with a normal glucose tolerance during the OGTT. We 
documented that, although baseline levels of GLP-1 were 
similar between obese and normal-weight children, the 
obese group showed higher secretion of GLP-1 during an 
oral glucose load. This secretion of GLP-1 was found to 
be influenced by baseline IR and fasting glycemic levels 
and emerged to be associated with insulin secretion 
during OGTT. GLP-1 is known to have several beneficial 
effects on glucose regulation. It stimulates endogenous 
insulin secretion in response to oral load, suppresses 
glucagon secretion leading to reduced hepatic glucose 
production, extra-pancreatic effects, as it improves 
glucose elimination [7, 8]. Taking into consideration all 
these effects, it might be speculated that GLP-1 changes 
documented in obese pre-pubertal children after glucose 
load may represent an early adaptive response to induce 
a greater insulin secretion to overcome IR. The peak 
levels of GLP-1 preceded the response of insulin spike, 
suggesting a directed relationship between the increased 
GLP-1 release and insulin secretion by the β-cells. There-
fore, we hypothesized that an increase in GLP-1 secre-
tion might explain or at least in part contribute to higher 
levels of insulin in obese children, ensuring a return to 
blood glucose levels to normal at the end of load curve. 
However, the study design does not allow to differenti-
ate whether elevated levels of GLP-1 in obese children are 
due to a compensatory increase in secretion or reflect a 
state of resistance of GLP-1. Therefore, further studies are 
needed to better clarify this question.
A limitation of our study is the small sample size. In 
addition, only GLP-1 values have been evaluated without 
taking into consideration the possible role of other gut 
secreted hormones. It needs further evaluation on larger 
samples and complete gut hormone patterns to confirm 
the results of this study. Furthermore, indirect measures 
of insulin secretion have been evaluated in this study, 
therefore studies evaluating β-cell function by the 
hyperglycemic clamp might be required to confirm our 
results.
In conclusion, in this study we showed that obese 
pre-pubertal children are more insulin resistant and 
have higher levels of insulin during an OGTT compared 
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to healthy normal-weight subjects. The higher levels of 
insulin were associated with increased levels of GLP-1. 
These changes might likely represent a compensatory 
mechanism to avoid postprandial hyperglycemia and 
allow a normal glucose tolerance. Further studies are 
required in this age group to better characterize the effect 
of GLP-1 concentrations on the regulation of glucose 
metabolism.
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